Wilson celebrates the first U.S. patient to complete gene therapy for sickle cell, but says advocacy must continue.

It has been nearly two years since Pfizer’s sickle cell disease (SCD) therapy Oxbryta was approved in the UK, but patients will now be able to access the treatment after an agreement was reached ...

Almost a year after two historic approvals, Pfizer is pulling a sickle cell disease treatment from the market, and the outlook for patients feels shakier.

Many individuals with sickle cell anemia undergoing controlled ovarian hyperstimulation (COH) with oocyte cryopreservation ...

Sickle cell patient files lawsuit against Global Blood Therapeutics, a wholly owned subsidiary of Pfizer, alleging harm from medication. The lawsuit, filed on Hardiman's behalf by the law firm ...

Andrew Fein, an analyst from H.C. Wainwright, reiterated the Hold rating on Fulcrum Therapeutics (FULC – Research Report). The associated ...

When Pfizer acquired Global Blood Therapeutics in October 2022, the flagship drug in the company’s portfolio was Oxbryta, a groundbreaking treatment that targets the root cause of sickle cell ...

Beam’s medicine uses a technology known as base editing to activate a gene in stem cells collected from people with sickle cell disease, an inherited blood condition that can cause debilitating pain ...

Oxbryta, approved in 2019 to treat sickle cell disease, was intended to reduce pain and improve red blood cell health. However, recent clinical trials revealed that the drug was linked to ...